Allena Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$93M
Industry:Biotech
Founded:2011
Lead Investor(s):HBM Partners

Estimated Revenue & Financials

  • Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.
  • Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
  • Allena Pharmaceuticals's estimated revenue per employee is $116,250
  • Allena Pharmaceuticals's total funding is $93M.

Employee Data

  • Allena Pharmaceuticals has 52 Employees.
  • Allena Pharmaceuticals grew their employee count by 18% last year.
  • Allena Pharmaceuticals currently has 5 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.

keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power

52

Number of Employees

$6M

Revenue (est)

5

Current Jobs

18%

Employee Growth %

$93M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Stephen KrausManager, Engineering
Hugh WightVP Technical Operations
Janet GirouxManager of Corporate Operations
Patrick NormanManager Of Contract Manufacturing
Jeremy KerrickManager Of Contract ManufacturingEmail Available
Kate HoffmanDirector, Clinical & Medical Affairs
Todd BanasSenior Director, Contract Manufacturing
Jason VieiraQa ManagerEmail Available
Claire ColemanSenior DirectorEmail Available
Stephen YuVice President, Quality Assurance

Allena Pharmaceuticals News

09/03/2019 - Allena Pharmaceuticals: Unique Treatment For Enteric Hyperoxaluria Not Reflected In Valuation

Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type ...

09/08/2019 - -$0.48 EPS Expected for Allena Pharmaceuticals Inc (NASDAQ:ALNA) This Quarter

Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...

09/03/2019 - Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company ...

Allena Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-11-17$15.0MABessemer Venture Partners, Frazier HealthcareArticle
2014-12-05$25.0MBHBM PartnersArticle
2015-12-10$53.0MCMultipleArticle

Allena Pharmaceuticals Executive Hires

DateNameTitleReference
2015-04-17Louis BrennerChief Operating OfficerArticle
2016-09-08Edward WholihanCFOArticle